Natco Pharma expects India, Brazil, and Canada markets to be its revenue drivers during the current financial year, recording growth of 30 percent to 40 percent. The India business alone is likely to grow by about 15 percent to 20 percent. The second driver will be Brazil. Brazil did not do well for many years, so company has some very good launches this year, and that should drive earnings. In Canada, Natco is anticipating a couple of launches and a couple of favorable settlements. If they all come through, drug maker expects the three markets to grow at 30 percent to 40 percent. India is expecting about eight to 10 launches this year.
The company has recorded consolidated total revenue of Rs 2225 crore for the year ended March 31, 2019, as against Rs 2242 crore in the previous year, a slight decline of less than 1 percent year-over-year. The net profit for the period on a consolidated basis was Rs 642.4 crore as against Rs 695 crore for the last year, showing a decline of 7.6 percent. The Indian business stood at Rs 735 crore while that of Canada and Brazil at Rs 96 crore and Rs 33 crore respectively.